雄激素受体、Ki-67在三阴性乳腺癌中的表达以及与预后的关系

Expression of Androgen Receptor and Ki-67 in Triple-negative Breast Cancer and Its Association with Prognosis

摘要

目的 探讨雄激素受体和Ki-67在三阴性乳腺癌（TNBC）中的表达,并研究它们与患者预后的关系。方法 选择了朝阳市中心医院2015年1月~2020年5月期间治疗的TNBC女性患者88例作为观察组,同时纳入了非三阴性乳腺癌（NTNBC）女性患者89例作为对照组。我们检测了AR和Ki-67的表达情况,并观察它们在TNBC中的表达差异,同时分析了它们与患者预后的关系。结果 AR在观察组的表达率低于对照组（P<0.05）,而Ki-67在观察组中的表达率高于对照组（P<0.05）。AR和Ki-67的表达均与肿瘤直径以及淋巴结转移个数有关（P<0.05）。COX回归分析显示,病理分级、淋巴结转移个数、AR和Ki-67表达情况是影响TNBC预后的独立影响因素(P<0.05)。结论 AR和Ki-67与TNBC的预后密切相关,AR阳性表达和Ki-67低表达的患者提示预后较好,生存时间更长。

Abstract

Objective To investigate the expression of androgen receptor (AR) and Ki-67 in triple-negative breast cancer, and to study their relationship with patients' prognosis. Methods Eighty-eight female TNBC patients treated at Chaoyang Central Hospital from January 2015 to May 2020 were included in the observation group, while 89 female NTNBC patients were included as a control group. We examined the expression of AR and Ki-67 and observed the differences in their expression in triple-negative breast cancer, and analysed their relationship with patients' prognosis. Results The expression rate of AR in the observation group was lower than that in the control group (P<0.05), while the expression rate of Ki-67 in the observation group was higher than that in the control group (P<0.05). The expression of AR and Ki-67 is related to tumor diameter and the number of lymph node metastases (P<0.05). COX regression analysis showed that pathological grade, number of lymph node metastases, AR and Ki-67 expression were independent influences on the prognosis of triple-negative breast cancer (P<0.05). Conclusion AR and Ki-67 were closely related to the prognosis of triple-negative breast cancer. Patients with positive AR expression and low Ki-67 expression suggested a better prognosis and longer survival time.

关键词

三阴性乳腺癌 / AR / Ki-67 / 预后

Key words

triple negative breast cancer / androgen receptor / Ki-67 / prognosis

[1] Wilkinson L, Gathani T.Understanding breast cancer as a global health concern[J]. Br J Radiol, 2022, 95(1130): 20211033.
[2] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013.
[4] Bianchini G, Balko JM, Mayer IA, et al.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
[5] Baranova A, Krasnoselskyi M, Starikov V, et al.Triple-negative breast cancer: current treatment strategies and factors of negative prognosis[J]. J Med Life, 2022, 15(2): 153-161.
[6] Zhu X, Chen L, Huang B, et al.The prognostic and predictive potential of Ki-67 in triple-negative breast cancer[J]. Sci Rep, 2020, 10(1): 225.
[7] Leon-Ferre RA, Goetz MP.Advances in systemic therapies for triple negative breast cancer[J]. Bmj, 2023, 381: e071674.
[8] 许人元,王晓东. TNBC的治疗进展[J]. 中国普外基础与临床杂志,2020,27(8)1033-1037.
[9] Wasmuth EV, Broeck AV, Laclair JR, et al.Allosteric interactions prime androgen receptor dimerization and activation[J]. Mol Cell, 2022, 82(11): 2021-2031.
[10] Tan MH, Li J, Xu HE, et al.Androgen receptor: structure, role in prostate cancer and drug discovery[J]. Acta Pharmacol Sin, 2015, 36(1): 3-23.
[11] Li D, Zhou W, Pang J, et al.A magic drug target: Androgen receptor[J]. Med Res Rev, 2019, 39(5): 1485-1514.
[12] Yu X, Yi P, Hamilton RA, et al. Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes[J]. Mol Cell, 2020, 79(5): 812-823.e4.
[13] Anestis A, Zoi I, Papavassiliou AG, et al.Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights[J]. Molecules, 2020, 25(2): 358-368.
[14] Yin L, Duan JJ, Bian XW, et al.Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61.
[15] Gucalp A, Tolaney S, Isakoff SJ, et al.Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer[J]. Clin Cancer Res, 2013, 19(19): 5505-5512.
[16] Astvatsaturyan K, Yue Y, Walts AE, et al.Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features[J]. PLoS One, 2018, 13(6): e0197827.
[17] Mcnamara KM, Yoda T, Takagi K, et al.Androgen receptor in triple negative breast cancer[J]. J Steroid Biochem Mol Biol, 2013, 133: 66-76.
[18] Wang C, Pan B, Zhu H, et al.Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis[J]. Oncotarget, 2016, 7(29): 46482-46491.
[19] Safarpour D, Pakneshan S, Tavassoli FA.Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?[J]. Am J Cancer Res, 2014, 4(4): 353-368.
[20] Traina TA, Miller K, Yardley DA, et al.Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer[J]. J Clin Oncol, 2018, 36(9): 884-890.
[21] Scholzen T, Gerdes J.The Ki-67 protein: from the known and the unknown[J]. J Cell Physiol, 2000, 182(3): 311-322.
[22] Isola J, Helin H, Kallioniemi OP.Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells[J]. Histochem J, 1990, 22(9): 498-506.
[23] Gerdes J, Lemke H, Baisch H, et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4): 1710-1715.
[24] Ibrahim T, Farolfi A, Scarpi E, et al.Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact[J]. Oncology, 2013, 84(3): 150-157.
[25] Nagao K, Yamamoto Y, Hara T, et al.Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml[J]. Jpn J Clin Oncol, 2011, 41(4): 555-564.
[26] van den Ende NS, Nguyen AH, Jager A, et al. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review[J]. Int J Mol Sci, 2023, 24(3): 2969-2980.
[27] Liu J, Wang S, Wang C, et al.Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy[J]. Exp Ther Med, 2021, 21(3): 247.
[28] Guestini F, Ono K, Miyashita M, et al.Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2019, 173(2): 275-288.
[29] Oshi M, Newman S, Murthy V, et al.ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer[J]. Cancers (Basel), 2020, 12(10): 2758.